These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37543081)

  • 1. Dosages of Nutrient Supplements and Potential Long-Term Toxicity in Attention-Deficit/Hyperactivity Disorder Micronutrient Study.
    Elmrayed S
    J Am Acad Child Adolesc Psychiatry; 2023 Nov; 62(11):1170-1171. PubMed ID: 37543081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youths: A Placebo-Controlled Randomized Clinical Trial.
    Johnstone JM; Hatsu I; Tost G; Srikanth P; Eiterman LP; Bruton AM; Ast HK; Robinette LM; Stern MM; Millington EG; Gracious BL; Hughes AJ; Leung BMY; Arnold LE
    J Am Acad Child Adolesc Psychiatry; 2022 May; 61(5):647-661. PubMed ID: 34303786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of an international randomized placebo-controlled trial of a 36-ingredient micronutrient supplement for children with ADHD and irritable mood: The Micronutrients for ADHD in Youth (MADDY) study.
    Johnstone JM; Leung B; Gracious B; Perez L; Tost G; Savoy A; Hatsu I; Hughes A; Bruton A; Arnold LE
    Contemp Clin Trials Commun; 2019 Dec; 16():100478. PubMed ID: 31763491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo-controlled trial.
    Rucklidge JJ; Eggleston MJF; Johnstone JM; Darling K; Frampton CM
    J Child Psychol Psychiatry; 2018 Mar; 59(3):232-246. PubMed ID: 28967099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineral-Vitamin Treatment Associated with Remission in Attention-Deficit/Hyperactivity Disorder Symptoms and Related Problems: 1-Year Naturalistic Outcomes of a 10-Week Randomized Placebo-Controlled Trial.
    Darling KA; Eggleston MJF; Retallick-Brown H; Rucklidge JJ
    J Child Adolesc Psychopharmacol; 2019 Nov; 29(9):688-704. PubMed ID: 31343273
    [No Abstract]   [Full Text] [Related]  

  • 6. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement.
    Rucklidge JJ; Johnstone J; Gorman B; Boggis A; Frampton CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():163-71. PubMed ID: 24374068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we predict treatment response in children with ADHD to a vitamin-mineral supplement? An investigation into pre-treatment nutrient serum levels, MTHFR status, clinical correlates and demographic variables.
    Rucklidge JJ; Eggleston MJF; Darling KA; Stevens AJ; Kennedy MA; Frampton CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():181-192. PubMed ID: 30217770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
    Winters DE; Fukui S; Leibenluft E; Hulvershorn LA
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):298-305. PubMed ID: 29708762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin-Mineral Treatment of ADHD in Adults.
    Rucklidge JJ; Frampton CM; Gorman B; Boggis A
    J Atten Disord; 2017 Apr; 21(6):522-532. PubMed ID: 24804687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA).
    Fernández de la Cruz L; Simonoff E; McGough JJ; Halperin JM; Arnold LE; Stringaris A
    J Am Acad Child Adolesc Psychiatry; 2015 Jan; 54(1):62-70.e3. PubMed ID: 25524791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Observational Preliminary Study on the Safety of Long-Term Consumption of Micronutrients for the Treatment of Psychiatric Symptoms.
    Rucklidge JJ; Eggleston MJF; Ealam B; Beaglehole B; Mulder RT
    J Altern Complement Med; 2019 Jun; 25(6):613-622. PubMed ID: 31081672
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study.
    Gordon HA; Rucklidge JJ; Blampied NM; Johnstone JM
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):783-98. PubMed ID: 26682999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial.
    Rucklidge JJ; Frampton CM; Gorman B; Boggis A
    Br J Psychiatry; 2014; 204():306-15. PubMed ID: 24482441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Changes in Blood Nutrient Levels Mediate Treatment Response in Children and Adults With ADHD Consuming a Vitamin-Mineral Supplement?
    Rucklidge JJ; Eggleston MJF; Boggis A; Darling K; Gorman B; Frampton CM
    J Atten Disord; 2021 Jun; 25(8):1107-1119. PubMed ID: 31707909
    [No Abstract]   [Full Text] [Related]  

  • 16. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Crippa A; Tesei A; Sangiorgio F; Salandi A; Trabattoni S; Grazioli S; Agostoni C; Molteni M; Nobile M
    Eur Child Adolesc Psychiatry; 2019 Apr; 28(4):571-583. PubMed ID: 30246216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
    Findling RL; Adler LA; Spencer TJ; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):80-89. PubMed ID: 30694697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Accumulating Evidence for the Benefit of Micronutrients for Children With Attention-Deficit/Hyperactivity Disorder.
    Stevenson J
    J Am Acad Child Adolesc Psychiatry; 2022 May; 61(5):599-600. PubMed ID: 34416292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.